Syndax unveils SNDX-4321 (allosteric EGFRi) and SNDX-62122 (menin inhibitor) at R&D event

Syndax Pharmaceuticals Inc

SNDX-4321: novel mutant-selective allosteric EGFR inhibitor for NSCLC; IND expected by end of 2026, Phase 1 in 2027.
SNDX-62122: first next-gen menin inhibitor from internal library; IND and Phase 1 in MF expected in 2027.
Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26.
Revumenib Phase 1/2 trial in MF expected to initiate in 4Q26 with initial data in H2 2027.
Company highlights late-stage revumenib and axatilimab programs in acute leukemia and chronic GVHD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.